This research study is checking if a combination of investigational medications can safely help treat pancreatic cancer that has spread. The study involves immunotherapy, a treatment that helps the body's defense system fight cancer cells. Participants will be randomly placed in two groups, receiving different treatments every two weeks. The study lasts up to 2 years, with follow-up visits for 12 months after treatment.

• Participants need to be 18 years or older, have specific types of pancreatic cancer, and have tried other treatments first.
• The study will include about 46 people, and participants must be willing to undergo regular tumor biopsies.
• Participants cannot join if they have certain medical conditions or allergies, or if they are taking specific medications.

This study is in Phase I/II, meaning researchers are looking at the safety and how well the investigational medications might work. The U.S. Food and Drug Administration (FDA) has not yet approved these medications for treating any disease. Participants should talk with their doctor to understand if they meet all the requirements to join.